PEGS: The Essential Protein Engineering Summit is one of the industry’s most preeminent events that inspires accelerated biotherapeutic protein drug development. This weeklong event attracts over 2,300 international participants, and features nearly 400 presentations by world renowned leaders from pharma, academia, and government showcasing case studies, cutting edge data, insight and perspective. Conference programs include a broad spectrum of topics including protein and antibody engineering, cancer immunotherapy, oncology, and emerging therapeutics. For more information, please visit www.pegsummit.com.
Mark Throsby, Ph.D, CSO will be presenting in the oncology stream on Monday, April 30, 2018 at 2.20 pm EST during the Problem-Solving Breakout Discussions.
Bispecific Antibodies – Beyond T Cell Recruitment
- Can the T cell recruitment approach work outside hematological cancers?
- How to select target combinations for bispecific approaches?
- Design or screen?
- What is going to be the best format?
John de Kruif, Ph.D, CTO will be presenting in the engineering stream on Friday, May 4, 2018 at 2.10 pm EST.
A New Approach for Generating Bispecific Antibodies Based on a Common Light Chain Format and the Stable Architecture of Human Immunoglobulin G1
We describe an approach for generating bispecific antibodies using common light chains and the stable architecture of human immunoglobulin G1. We used iterative experimental validation and computational modeling to identify an Fc variant pair that drives efficient heterodimerization of the antibody heavy chains. Long-term accelerated stability assays confirmed that this molecule is highly stable and has excellent biophysical characteristics. We show how this molecule is integrated in our discovery platform.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus’ website, www.merus.nl.